CPIX - Cumberland Pharmaceuticals Inc.
| Previous Close | 5.16 |
| Open | 5.37 |
| Bid | 5.16 x 800 |
| Ask | 7.67 x 1800 |
| Day's Range | 5.16 - 5.37 |
| 52 Week Range | 4.19 - 6.99 |
| Volume | 8,060 |
| Avg. Volume | 28,584 |
| Market Cap | 78.349M |
| Beta (3Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.32 |
| Earnings Date | Feb 24, 2020 - Feb 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.75 |
- Zacks
New Strong Sell Stocks for December 4th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- PR Newswire
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex™ Product Line
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for RediTrex™, its new line of methotrexate products.
- Thomson Reuters StreetEvents
Edited Transcript of CPIX earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 Cumberland Pharmaceuticals Inc Earnings Call
- PR Newswire
New Study Reveals Real-World Usage of Vibativ® In a Variety Of Infections
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces a new online publication in Drugs - Real World Outcomes, detailing the positive clinical outcomes that resulted from treating multiple infection types with Vibativ®, including complicated skin and skin structure infections (cSSSI), bone and joint infections, bacteremia and endocarditis, and lower respiratory tract infections (LRTI).
- PR Newswire
Cumberland Pharmaceuticals Reports 22% Revenue Growth In The Third Quarter
NASHVILLE, Tenn. , Nov. 12, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced ...
- Zacks
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.
- Zacks
What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?
Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.
- Zacks
Cumberland Pharmaceuticals (CPIX) to Report Q3 Results: Wall Street Expects Earnings Growth
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Cumberland Pharmaceuticals To Announce Third Quarter 2019 Financial Results
NASHVILLE, Tenn. , Nov. 5, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2019 financial results after the market closes on Tuesday, ...
- Simply Wall St.
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Zacks
Cumberland Pharmaceuticals (CPIX) Outpaces Stock Market Gains: What You Should Know
Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.
- PR Newswire
New Study Reveals Superiority Of Vibativ® Over Vancomycin In Select Patients With Bacterial Pneumonia
NASHVILLE, Tenn., Oct. 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a U.S. specialty pharmaceutical company announces a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of telavancin compared to vancomycin within a subset of patients who were enrolled in phase 3 ATTAIN trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. Cumberland manufactures and distributes telavancin under the brand name Vibativ®. Vibativ® (telavancin) is a patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia.
- Simply Wall St.
Does Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Pay Matter?
A. Kazimi has been the CEO of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) since 1999. First, this article will...
- PR Newswire
Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program
NASHVILLE, Tenn., Sept. 24, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced FDA Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. Food and Drug Administration (FDA) has cleared Cumberland's application to study ifetroban in DMD patients, 7 years of age and older. In addition, Cumberland has been awarded just over $1 million in funding from the FDA through their Orphan Drug Grant program to support a Phase II DMD clinical study.
- Zacks
Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
Cumberland (CPIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Zacks
Theravance Announces Positive Early Data on JAK Inhibitor
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
- Thomson Reuters StreetEvents
Edited Transcript of CPIX earnings conference call or presentation 14-Aug-19 8:30pm GMT
Q2 2019 Cumberland Pharmaceuticals Inc Earnings Call
- Zacks
Here is Why Growth Investors Should Buy Cumberland (CPIX) Now
Cumberland (CPIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
